Page 9 - hypertension_newsletter6
P. 9
REFLECTIONS
Hypertension
Hypertension Global Newsletter #6 2024
TREATMENT AND ADHERENCE Hypertension
Systolic blood pressure time in target range and incident atrial fibrillation in
patients with hypertension: Insights from the SPRINT trial.
Wang J, et al. Hypertension. 2023 Nov;80(11):2306-2314.
The Systolic Blood Pressure Intervention Trial (SPRINT) was a randomised controlled trial comparing intensive (<120 mmHg) and
standard (<140 mmHg) SBP interventions in participants with hypertension. This post-hoc analysis evaluated the prognostic value
of SBP time in target range (TTR) for incident atrial fibrillation (AF) in patients with hypertension. Longer hypertension duration and
greater BP variability were found in previous studies to be associated with an increased risk of AF; therefore, maintaining BP with a
target range continuously and stably may provide benefits for preventing AF.
The TTR is a novel concept that reflects the consistency of effective BP control. The measurement incorporates both the average BP
value and the degree of BP variability, as well as variation within and out of the target range and well-controlled time. The TTR was
110–130 mmHg for the intensive arm, while for the standard arm, it was 120–140 mmHg.
Among 7939 participants included in this analysis, 187 incident AF cases occurred during a median of 3.8 years of follow-up.
TABLE OF CONTENTS
